Key Takeaways
- Sage is laying off around 165 employees, including some corporate leaders, to preserve cash following a series of R&D setbacks.
- It is the second round of layoffs for Sage after the company cut 40% of its workforce last year after missing the approval of Zurzuvae in major depressive disorder.
- Chief financial officer Kimi Iguchi and chief technology and innovation officer Matt Lasmanis are among the management that will depart.
Sage Therapeutics is laying off 33% of its workforce, including 55% of the company’s R&D organization and some of its corporate leadership staff, as it seeks to preserve cash following...
It’s the second round of significant layoffs for Sage in two years. Last year, the company cut 40% of its workforce after its depression drug Zurzuvae (zuranolone) was approved...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
